Calcitonin as a marker for bronchogenic cancer: a prospective study.
Cancer
; 44(2): 680-4, 1979 Aug.
Article
in En
| MEDLINE
| ID: mdl-476577
A prospective study was done of serum calcitonin (HCT) levels in 61 patients with bronchogenic cancer. Initially, 52% of patients had hypercalcitonemia. Hypercalcitonemia was not confined to patients with any particular histologic type. Seventy-eight percent of those with high calcitonin remained normocalcemic. There was no correlation between high calcitonin levels and osseous metastases. Selective thyroid venous sampling delineated two types of hypercalcitonemia: thyroidal and ectopic. To date, the ectopic type has been associated with the small cell bronchogenic carcinoma. High initial calcitonin levels decreased significantly in 75% of patients on antitumor therapy. In 13 evaluable patients calcitonin levels mirrored clinical status changes 67% of the time. Calcitonin may be a useful marker to assess the results of therapy in patients with bronchogenic cancer.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Calcitonin
/
Carcinoma, Bronchogenic
/
Hormones, Ectopic
/
Lung Neoplasms
Type of study:
Observational_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Cancer
Year:
1979
Document type:
Article